Global Short Bowel Syndrome Market Size, Share, Forecast Report, 2020-2027
The global Short Bowel Syndrome market garnered revenue around USD 563.8 Million in 2019 and projected to reach USD 4.6 Billion in 2027, with at a compound annual growth rate (CAGR) 28% throughout the estimate period from 2020 to 2027. The global market is driven by increase in awareness and acceptance of the short bowel syndrome treatment. The global short bowel syndrome market has been segmented based on drug class and region. In terms of drug class, the global short bowel syndrome market has been classified into glucagon-like peptide-2 (GLP-2), growth hormone, glutamine, and others
The trend of developing new biopharmaceuticals is favoring growth of the short bowel syndrome market. For instance, Huons - a manufacturer of pharmaceutical products, announced partnership with Genexine - a clinical-stage biotechnology company, to develop new biopharmaceuticals.
Cross promotion is another driver that is enhancing the credibility of companies who are collaborating in the short bowel syndrome market landscape. Increasing demand for therapeutic drugs and biobetter drugs for rare diseases is another driver that is catalyzing market expansion. Manufacturers are increasing research efforts in immunotherapeutic drugs to support the biopharmaceutical industry.
This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.
The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Short Bowel Syndrome market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Short Bowel Syndrome market growth.
The global Short Bowel Syndrome market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.
Major manufacturers analysed under this study comprises:
the global short bowel syndrome market. These include Shire plc (Takeda Pharmaceutical Company Limited), Zealand Pharma A/S, Sancilio & Company, Inc., OxThera, Nutrinia Ltd., Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc. (Pfizer Inc.), Merck KGaA, and Naia Pharmaceuticals, Inc.
This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:
Global Short Bowel Syndrome Market: Segmentation
- Short Bowel Syndrome Market, by Drug Class
- Glucagon-like Peptide-2 (GLP-2)
- Growth Hormone
Regional Analysis and Forecast
Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:
- North America
- United States
- United Kingdom
- Rest of EU
- Asia Pacific
- Southeast Asia
- Rest of APAC
- Central & South America
- Rest of Central & South America
- Middle East and Africa
- Saudi Arabia
- Rest of MEA